Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.

This is written in the approval document as:

Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Citation

Trametinib and Dabrafenib Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed on 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) BRAF p.V600E Melanoma Dabrafenib, Trametinib
HSE (1) BRAF p.V600K Melanoma Dabrafenib, Trametinib